Literature DB >> 8112834

Immunoblot analyses of chimpanzee sera after infection and after immunization and challenge with Mycoplasma pneumoniae.

G Franzoso1, P C Hu, G A Meloni, M F Barile.   

Abstract

Consecutive weekly or biweekly serum specimens obtained during a 3- or 4-month study from 16 chimpanzees were examined by immunoblot analyses to identify the immunogenic components of Mycoplasma pneumoniae. Six experimentally infected chimpanzees showed significant signs of overt disease, including cough, pharyngitis, rhinitis, fever, and loss of appetite. The sera of these infected chimpanzees recognized from 17 to 20 protein bands. Two control chimpanzees that were not inoculated were included in the study. Three chimpanzees immunized with a formalin-inactivated OSU-1A vaccine and three chimpanzees immunized with an experimental acellular vaccine showed minimal signs of disease on challenge. After challenge, the serum immunoblot responses of the immunized chimpanzees were similar to those of the infected chimpanzees. Before challenge, the sera of two previously infected chimpanzees recognized protein bands of 169 (which comigrated with the P1 adhesin), 148, 130, 117, 86, 61, 44, 35, 30, and 29 kDa. After challenge, the previously infected chimpanzees showed the most intense serum immunoblot responses and were most protected against colonization and disease. The sera from each of the 16 chimpanzees examined recognized a large number of immunogenic components, and the serum immunoblot responses were virtually identical to those of patients. Sera from each chimpanzee and patient recognized 169-, 148-, 130-, 117-, 86-, 44-, and 35-kDa bands and many of them recognized 67-, 63-, 61-, 56-, 32-, 30-, and 29-kDa protein bands.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8112834      PMCID: PMC186217          DOI: 10.1128/iai.62.3.1008-1014.1994

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  47 in total

1.  Species-specific monoclonal antibody to a 43,000-molecular-weight membrane protein of Mycoplasma pneumoniae.

Authors:  R D Madsen; F A Saeed; O Gray; B M Fendly; S R Coates
Journal:  J Clin Microbiol       Date:  1986-10       Impact factor: 5.948

2.  Characteristics of virulent, attenuated, and avirulent Mycoplasma pneumoniae strains.

Authors:  R P Lipman; W A Clyde; F W Denny
Journal:  J Bacteriol       Date:  1969-11       Impact factor: 3.490

3.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

4.  Influence of cell shape and surface charge on attachment of Mycoplasma pneumoniae to glass surfaces.

Authors:  J Feldner; W Bredt; I Kahane
Journal:  J Bacteriol       Date:  1983-01       Impact factor: 3.490

5.  Serological comparison of virulent and avirulent Mycoplasma pneumoniae by monoclonal antibodies.

Authors:  P C Hu; A M Collier; W A Clyde
Journal:  Isr J Med Sci       Date:  1984-09

6.  Ciliostatic, hemagglutinating, and proteolytic activities in a cell extract of Mycoplasma pneumoniae.

Authors:  D K Chandler; M F Barile
Journal:  Infect Immun       Date:  1980-09       Impact factor: 3.441

7.  The principal protein antigens of isolates of Mycoplasma pneumoniae as measured by levels of immunoglobulin G in human serum are stable in strains collected over a 10-year period.

Authors:  A C Vu; H M Foy; F D Cartwright; G E Kenny
Journal:  Infect Immun       Date:  1987-08       Impact factor: 3.441

8.  Localization and biochemical characterization of the ORF6 gene product of the Mycoplasma pneumoniae P1 operon.

Authors:  G Layh-Schmitt; R Herrmann
Journal:  Infect Immun       Date:  1992-07       Impact factor: 3.441

9.  Long-term epidemiology of infections with Mycoplasma pneumoniae.

Authors:  H M Foy; G E Kenny; M K Cooney; I D Allan
Journal:  J Infect Dis       Date:  1979-06       Impact factor: 5.226

10.  Hamster challenge potency assay for evaluation of Mycoplasma pneumoniae vaccines.

Authors:  M F Barile; D K Chandler; H Yoshida; M W Grabowski; S Razin
Journal:  Infect Immun       Date:  1988-09       Impact factor: 3.441

View more
  3 in total

Review 1.  Mycoplasma pneumoniae and its role as a human pathogen.

Authors:  Ken B Waites; Deborah F Talkington
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

Review 2.  Molecular biology and pathogenicity of mycoplasmas.

Authors:  S Razin; D Yogev; Y Naot
Journal:  Microbiol Mol Biol Rev       Date:  1998-12       Impact factor: 11.056

3.  The proline-rich P65 protein of Mycoplasma pneumoniae is a component of the Triton X-100-insoluble fraction and exhibits size polymorphism in the strains M129 and FH.

Authors:  T Proft; H Hilbert; G Layh-Schmitt; R Herrmann
Journal:  J Bacteriol       Date:  1995-06       Impact factor: 3.490

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.